Science Explorer Back to mapMap
Discussion
Institution · Alliance Data (United States)

Most cited papers from Alliance Data (United States)

Alliance Data (United States)

What are the most cited papers from Alliance Data (United States)?

The most cited paper from Alliance Data (United States) is "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation" (Richard Maury Stone et al., 2017), with 2,258 citations. Next come "Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis" (1,941) and "Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases" (1,689).

Showing 50 of 61 papers. Every paper with more than 95 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation Richard Maury Stone et al. · New England Journal of Medicine Open access 23 Jun 2017 2,258
2 Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Armando E. Giuliano, Karla V. Ballman, Linda Mackie McCall et al. · JAMA Open access 12 Sep 2017 1,941
3 Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases Paul David Brown, Kurt A. Jaeckle, Karla V. Ballman et al. · JAMA Open access 26 Jul 2016 1,689
4 Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial Paul David Brown, Karla V. Ballman, Jane H. Cerhan et al. · The Lancet Oncology Open access 4 Jul 2017 1,218
5 Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes James W. Fleshman et al. · JAMA Open access 6 Oct 2015 1,114
6 Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy Elizabeth Smith, Herbert Pang, Constance Cirrincione et al. · JAMA Open access 3 Apr 2013 1,024
7 Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer Ann Woyach et al. · New England Journal of Medicine Open access Dec 2018 969
8 Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology Open access 19 Jan 2018 774
9 Fair, Transparent, and Accountable Algorithmic Decision-making Processes Bruno Lepri, Nuria Oliver, Emmanuel Letouzé et al. · Philosophy & Technology 14 Aug 2017 705
10 Mobile phone data for informing public health actions across the COVID-19 pandemic life cycle Nuria Oliver et al. · Science Advances Open access 27 Apr 2020 694
11 Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Judy Caroline Boughey, Linda Mackie McCall, Karla V. Ballman et al. · Annals of Surgery Open access 9 Sep 2014 442
12 Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer James W. Fleshman et al. · Annals of Surgery Open access 3 Aug 2018 415
13 Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Toni K. Choueiri, Colin Hessel, Susan Halabi et al. · European Journal of Cancer Open access 20 Mar 2018 406
14 Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503) Nasser Khaled Altorki et al. · The Lancet Respiratory Medicine Open access 12 Nov 2018 385
15 Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases Andrew L. Himelstein, Jared C. Foster, James L. Khatcheressian et al. · JAMA Open access 3 Jan 2017 367
16 Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer Brian Matthew Wolpin et al. · Nature Genetics Open access117 authors 3 Aug 2014 347
17 Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk et al. · Gastroenterology Open access 9 Oct 2014 329
18 International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium Corneel Coens et al. · The Lancet Oncology Open access 30 Jan 2020 323
19 Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Ethan Basch, Claus C. Becker, Lauren J. Rogak et al. · Clinical Trials Open access Dec 2020 256
20 Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) Michael Gnant et al. · Journal of Clinical Oncology Open access 7 Dec 2021 237
21 Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the A merican C ollege of S urgeons O ncology G roup Z 4033 ( A lliance) trial Damian Edward Dupuy, Hiran Chrishantha Fernando, Shauna L. Hillman et al. · Cancer Open access 19 Jun 2015 231
22 Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis Erin Lynn Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki et al. · JAMA Oncology Open access 12 Apr 2018 212
23 Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards Andrew Bottomley et al. · The Lancet Oncology 18 Oct 2016 204
24 Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia Konstanze Döhner et al. · Blood Open access 11 Dec 2019 200
25 Using misinformation as a political weapon: COVID-19 and Bolsonaro in Brazil Julie Ricard, Juliano Medeiros · Harvard Kennedy School Misinformation Review Open access 16 Apr 2020 192
26 Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Matthew H. G. Katz, Fang‐Shu Ou, Joseph M. Herman et al. · BMC Cancer Open access 27 Jul 2017 189
27 Growth of Ti3SiC2 thin films by elemental target magnetron sputtering Jens Emmerlich, Hans Högberg, Szilvia Sasvári et al. · Journal of Applied Physics 28 Oct 2004 182
28 A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072 on behalf of the ACOSOG investigators et al. · Annals of Surgical Oncology Open access 24 May 2016 173
29 Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial Sarah A. Holstein et al. · The Lancet Haematology Open access 17 Aug 2017 172
30 A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K Daniel J. Ma, Evanthia Galanis, S. Keith Anderson et al. · Neuro-Oncology Open access 18 Dec 2014 171
31 Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy Aziz Zaanan, Qian Shi, Julien Taı̈eb et al. · JAMA Oncology Open access 5 Oct 2017 152
32 Ethical machines: The human-centric use of artificial intelligence Bruno Lepri, Nuria Oliver, Alex Pentland · iScience Open access Mar 2021 149
33 BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas Priscilla Kaliopi Brastianos et al. · New England Journal of Medicine Open access 12 Jul 2023 146
34 Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 Evanthia Galanis et al. · Neuro-Oncology Open access 21 Aug 2017 139
35 CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer Stacey Shiovitz, Monica M. Bertagnolli, Lindsay Anne Renfro et al. · Gastroenterology Open access 21 May 2014 132
36 Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance) Arnaud Augert, Qing Zhang, Breanna M. Bates et al. · Journal of Thoracic Oncology Open access 19 Dec 2016 131
37 Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With AdvancedEGFR-Mutant Non–Small Cell Lung Cancer Thomas E. Stinchcombe, Pasi Antero Janne, Xiaofei Wang et al. · JAMA Oncology Open access 8 Aug 2019 128
38 Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆ Romain Cohen, Q. Shi, J. P. Meyers et al. · Annals of Oncology Open access 20 Jul 2021 126
39 CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design Kurt A. Jaeckle et al. · Neuro-Oncology Open access 13 Jul 2020 121
40 Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Ghassan K. Abou‐Alfa et al. · JAMA Oncology Open access 5 Sep 2019 120
41 Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254 Gita Thanarajasingam, Pamela J Atherton, Paul J. Novotny et al. · The Lancet Oncology Open access 12 Apr 2016 120
42 Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis Dirk De Ruysscher et al. · Annals of Oncology ReviewOpen access 19 Jul 2016 118
43 Moves on the Street: Classifying Crime Hotspots Using Aggregated Anonymized Data on People Dynamics Andrey Bogomolov, Bruno Lepri, Jacopo Staiano et al. · Big Data 14 Aug 2015 117
44 Racial Differences in BRAF / KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients Harry H. Yoon, Qian Shi, Steven R. Alberts et al. · JNCI Journal of the National Cancer Institute Open access 9 Jul 2015 115
45 Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma Mark Andrew Dickson, M. R. Mahoney, William D. Tap et al. · Annals of Oncology Open access 9 Aug 2016 114
46 Predicting response and survival in chemotherapy-treated triple-negative breast cancer Aleix Prat et al. · British Journal of Cancer Open access 7 Aug 2014 113
47 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET David J. Straus, Sin‐Ho Jung, Brandelyn Nicole Pitcher et al. · Blood Open access 26 Jul 2018 111
48 Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study Celalettin Üstün et al. · Leukemia Open access 9 May 2019 110
49 High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 Jeffrey A. Bogart, Xiaofei Wang, Gregory A. Masters et al. · Journal of Clinical Oncology Open access 9 Jan 2023 106
50 Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 Wyndham Hopkins Wilson, Jung sin-Ho, Brandelyn Nicole Pitcher et al. · Blood 2 Dec 2016 106

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.